Novartis AG
Paediatric Compositions For Treating Multiple Sclerosis

Last updated:

Abstract:

The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C.sub.2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.

Status:
Application
Type:

Utility

Filling date:

4 Mar 2020

Issue date:

25 Jun 2020